This week I gave the annual City of London Law Society lecture in Gray's Inn. Chaired by Sir Peter Gross and followed by discussants, Stephen Kenny KC and Julie Norris of Kingsley Napley. The talk is a highly abridged version of the the first two of my Hamlyn Lectures (click through to read the full text of those). The question before us tonight is: Do we need an ethical reset?

YouTube video by Wesley Safadão

Just released: Cellectis reports 89.1M voting rights from 100.3M total shares. See complete shareholding structure and latest capital distribution details.

9 track album

Idorsia Pharmaceuticals CEO André Muller brings extensive biotech leadership experience to Cellectis board. Two directors step down as company reshapes governance. Learn more.

Cellectis (NASDAQ: CLLS) published a Nature Communications article on Nov 19, 2025 describing a non-viral gene insertion process using circular single-stranded DNA (CssDNA) donor templates combined with TALEN gene editing in hematopoietic stem and progenitor cells (HSPCs).Key results: CssDNA produced 3–5x higher knock-in efficiency than linear ssDNA with efficiencies surpassing 40%; CssDNA enabled insertion at multiple HSPC loci and worked in primary T cells; CssDNA-edited HSPCs showed higher engraftment and maintenance of edits in a murine model versus AAV6-edited HSPCs.This work positions CssDNA as an efficient non-viral strategy to expand durable gene and cell therapy options.

French biotech Cellectis (CLLS) discloses 100,325,229 total shares and 89,428,230 voting rights as of August 31, 2025. Monthly regulatory update per Article 223-16.

Cellectis (NASDAQ: CLLS) is hosting an R&D Day in New York City on October 16, 2025 to present pipeline progress for its allogeneic cell therapy program.Leadership and key opinion leaders will present the complete Phase 1 dataset and outline the pivotal Phase 2 trial design and commercial opportunity for lasme-cel (UCART22) in relapsed/refractory B‑ALL. The event runs 08:30–10:30 a.m. ET, is in-person and live via webcast, and a replay will be posted on the company website.

Cellectis (CLLS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs and strategic partnerships. The company maintains a strong cash position of $264 million, providing runway into mid-2027.Key pipeline updates include: UCART22 Phase 1 data and development strategy expected in Q3 2025, with FDA granting Orphan Drug and Rare Pediatric Disease DesignationsUCART20x22 Phase 1 study in NHL ongoing with readout expected late 2025Three active programs in collaboration with AstraZenecaNotable corporate developments include AstraZeneca's $140 million additional equity investment and the completion of European Investment Bank financing drawdown of €40 million. The company has deprioritized UCART123 development to focus on BALLI-01 and NATHALI-01 studies.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated

Cellectis (NASDAQ: CLLS) announced an Arbitral Tribunal decision dated December 15, 2025 in its arbitration with Les Laboratoires Servier and IRIS SARL relating to the March 6, 2019 License Agreement.The Tribunal ordered a partial termination of the License Agreement with respect to product UCART19 V1 (also called ALLO-501) and provided that Cellectis shall, at Allogene’s request, engage in good-faith discussions about granting a direct license to UCART19 V1. All other claims between the parties were dismissed.